In addition to PD-1/PD-L1 inhibitors, recent studies have also highlighted the importance of other immune checkpoints, such as CXCR3 and IL-15, in regulating the immune response to urinary tract tumors (86). Here, IL15 is linked to urinary system neoplasm.